Arcutis Biotherapeutics, Inc. (ARQT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 200M 400M 600M Q2 '22: 0 Q3 '22: 725K Q4 '22: 3.7M Q1 '23: 6.5M Q2 '23: 11.7M Q3 '23: 49M Q4 '23: 59.6M Q1 '24: 106.4M Q2 '24: 132.1M Q3 '24: 138.7M Q4 '24: 196.5M Q1 '25: 212.8M Q2 '25: 263.5M Q3 '25: 317.9M Q4 '25: 376.1M Q1 '26: 415.6M Q2 '26: 464M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 150M 300M 450M Q4 '23: 54.6M Q1 '24: 98.9M Q2 '24: 121.9M Q3 '24: 124.2M Q4 '24: 177.4M Q1 '25: 188.1M Q2 '25: 234.7M Q3 '25: 286M Q4 '25: 339.4M Q1 '26: 378M Q2 '26: 422.9M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '19: -43.1M Q1 '20: -64.8M Q2 '20: -91.9M Q3 '20: -115.6M Q4 '20: -136.6M Q1 '21: -144.1M Q2 '21: -150.5M Q3 '21: -169.3M Q4 '21: -206.5M Q1 '22: -233.1M Q2 '22: -256.8M Q3 '22: -304.5M Q4 '22: -301.6M Q1 '23: -315.3M Q2 '23: -316.2M Q3 '23: -248.4M Q4 '23: -241.1M Q1 '24: -196.5M Q2 '24: -179.8M Q3 '24: -181.9M Q4 '24: -128.4M Q1 '25: -121.3M Q2 '25: -85.8M Q3 '25: -38.2M Q4 '25: -12.2M Q1 '26: 3.2M Q2 '26: 34.3M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '19: -42M Q1 '20: -63.4M Q2 '20: -90.5M Q3 '20: -114.2M Q4 '20: -135.7M Q1 '21: -143.7M Q2 '21: -150.3M Q3 '21: -169.1M Q4 '21: -206.4M Q1 '22: -234.6M Q2 '22: -260M Q3 '22: -310.8M Q4 '22: -311.5M Q1 '23: -327.2M Q2 '23: -330.8M Q3 '23: -267.9M Q4 '23: -262.1M Q1 '24: -217.4M Q2 '24: -198.8M Q3 '24: -195.5M Q4 '24: -140M Q1 '25: -129.7M Q2 '25: -93.3M Q3 '25: -44.3M Q4 '25: -16.1M Q1 '26: -2.4M Q2 '26: 28.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

0 15M 30M 45M Q4 '23: 5M Q1 '24: 7.5M Q2 '24: 10.1M Q3 '24: 14.5M Q4 '24: 19.1M Q1 '25: 24.7M Q2 '25: 28.7M Q3 '25: 31.9M Q4 '25: 36.7M Q1 '26: 37.6M Q2 '26: 41.1M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow TTM

-300M -200M -100M 0 100M 200M 300M Q4 '19: -42.8M Q1 '20: -56.8M Q2 '20: -74.3M Q3 '20: -97.3M Q4 '20: -113M Q1 '21: -138.2M Q2 '21: -148.3M Q3 '21: -155.5M Q4 '21: -174.6M Q1 '22: -185.4M Q2 '22: -211.5M Q3 '22: -238.4M Q4 '22: -257.7M Q1 '23: -281.1M Q2 '23: -285.6M Q3 '23: -261.9M Q4 '23: -247.1M Q1 '24: -198.3M Q2 '24: -176.9M Q3 '24: -167.7M Q4 '24: -112.2M Q1 '25: -110.9M Q2 '25: -65.5M Q3 '25: -32.6M Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Free Cash Flow TTM

-300M -200M -100M 0 100M 200M 300M Q4 '19: -43.1M Q1 '20: -56.9M Q2 '20: -74.4M Q3 '20: -97.5M Q4 '20: -113.4M Q1 '21: -139.1M Q2 '21: -149.2M Q3 '21: -156.4M Q4 '21: -175.6M Q1 '22: -186M Q2 '22: -212.2M Q3 '22: -238.8M Q4 '22: -258M Q1 '23: -281.4M Q2 '23: -286.1M Q3 '23: -262.4M Q4 '23: -247.5M Q1 '24: -198.7M Q2 '24: -177M Q3 '24: -167.8M Q4 '24: -112.3M Q1 '25: -111.7M Q2 '25: -66.3M Q3 '25: -33.2M Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '20: 37.6M Q3 '20: 37.7M Q1 '21: 47.3M Q2 '21: 50M Q3 '21: 50.1M Q1 '22: 50.5M Q2 '22: 51.4M Q3 '22: 57.1M Q1 '23: 61.2M Q2 '23: 61.4M Q3 '23: 61.7M Q1 '24: 111M Q2 '24: 123.5M Q3 '24: 124.3M Q1 '25: 126K Q2 '25: 127M Q3 '25: 132.9M Q1 '26: 129.4K Q2 '26: 135.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-24.00 -16.00 -8.00 0.00 8.00 16.00 24.00 Q4 '19: -22.46 Q1 '20: -19.53 Q2 '20: -15.78 Q3 '20: -9.23 Q4 '20: -3.84 Q1 '21: -3.45 Q2 '21: -3.35 Q3 '21: -3.48 Q4 '21: -4.17 Q1 '22: -4.68 Q2 '22: -5.15 Q3 '22: -5.90 Q4 '22: -5.61 Q1 '23: -5.65 Q2 '23: -5.50 Q3 '23: -4.34 Q4 '23: -3.79 Q1 '24: -2.80 Q2 '24: -2.06 Q3 '24: -1.66 Q4 '24: -1.15 Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.